Osteosclerotic lesions in patients treated with gefitinib for lung adenocarcinomas: A sign of favorable therapeutic response

Skeletal Radiology

Volumn 41, Issue 4, 2012, Pages 409-414

  Yamashita, Yoshiko ^a   Aoki, Takatoshi ^a   Hanagiri, Takeshi ^a   Yoshii, Chiharu ^a   Mukae, Hiroshi ^a   Uramoto, Hidetaka ^a   Korogi, Yukunori ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Bone; CT; Gefitinib; Lung cancer; Metastasis

Indexed keywords

GEFITINIB; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

ADULT; AGED; ARTICLE; BONE METASTASIS; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FREQUENCY ANALYSIS; HUMAN; LUNG ADENOCARCINOMA; LUNG SURGERY; MALE; OSTEOLYSIS; OSTEOSCLEROSIS; PRIMARY TUMOR; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; THORAX RADIOGRAPHY; TREATMENT RESPONSE; ADENOCARCINOMA; CHEMICALLY INDUCED DISORDER; LUNG TUMOR; MIDDLE AGED; RADIOGRAPHY; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; OSTEOSCLEROSIS; QUINAZOLINES; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84862291070     PISSN: 03642348     EISSN: 14322161     Source Type: Journal    
DOI: 10.1007/s00256-011-1253-9     Document Type: Article

References (17)

1. Pao W, Zakowski M, Cordon-Cardo C, et al. Molecular characteristics of non-small cell lung cancer (NSCLC) patients sensitive to gefitinib. Proc Am Soc Clin Oncol 2004; 23: 623 s (abstract).
2. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol. 2003;21:2237-46. (Pubitemid 46621858)
3. Normanno N, De Luca A, Aldinucci D, et al. Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasis. Endocr Relat Cancer. 2005;12:471-82. (Pubitemid 40896460)
4. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205-16. (Pubitemid 30099779)
5. Coleman RE. Skeletal complications of malignancy. Cancer. 1997;80:1588-94. (Pubitemid 27444031)
6. Zampa G, Zampa G, Moscato M, Brannigan BW, Morabito A, Bell DW, et al. Prolonged control of bone metastases in non-small-cell lung cancer patients treated with gefitinib. Lung Cancer. 2008;60:452-4.
7. Satoh H, Ishikawa H, Ohara G, Kikuchi N, Sekizawa K. Prolonged response to gefitinib in bone metastasis. Med Oncol. 2009;26:102-2.
8. Okano Y, Nishio M. Efficacy of gefitinib in treatment of lung cancer patients with bone metastasis. Clin Calcium. 2008;18:527-33.
9. Conte PF, Latreille J, Mauriac L, et al. Delay in progression of bone metastasis in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. J Clin Oncol. 1996;14:2552-9. (Pubitemid 26300123)
10. Glover D, Lipton A, Keller A, et al. Intravenous pamidronate disodium treatment of bone metastasis in patients with breast cancer. A dose-seeking study. Cancer. 1994;74:2949-55. (Pubitemid 24361080)
11. Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med. 1996;335:1785-91. (Pubitemid 26412396)
12. Roodman GD. Biology of osteoclast activation in cancer. J Clin Oncol. 2001;19:3562-71. (Pubitemid 32734171)
13. Normanno N, Gullick WJ. Epidermal growth factor receptor tyrosine kinase inhibitors and bone metastases: different mechanisms of action for a novel therapeutic application? Endocr Relat Cancer. 2006;13:3-6.
14. Dawar AL, Farrugia AN, Condina MR, et al. Imatinib as a potential antiresorptive therapy for bone disease. Blood. 2006;107:4334-7. (Pubitemid 43801358)
15. Berman E, Nicolaides M, Maki RG, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med. 2006;354:2006-2013.
16. Chao HS, Chang CP, Chiu CH, et al. Bone scan flare phenomenon in non-small-cell lung cancer patients treated with gefitinib. Clin Nucl Med. 2009;34:346-9.
17. Yamaguchi T. Intertrabecular vertebral metastases: metastases only detectable on MR imaging. Semin Musculoskelet Radiol. 2001;5:171-5. (Pubitemid 32705950)